Macrocure Ltd (MCUR) is Downgraded by Credit Suisse to Underperform, Price Target at $1

Macrocure Ltd (MCUR) was Downgraded by Credit Suisse to ” Underperform” and the brokerage firm has set the Price Target at $1. Earlier the firm had a rating of “Neutral ” on the company shares. Credit Suisse advised their investors in a research report released on Jul 18, 2016.

Macrocure Ltd closed down -0.02 points or -1.25% at $1.58 with 1,32,386 shares getting traded on Friday. Post opening the session at $1.65, the shares hit an intraday low of $1.54 and an intraday high of $1.65 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

MacroCure Ltd. is a biotechnology company. The Company is focused on developing manufacturing and commercializing cell therapy products to address unmet needs in the treatment of chronic and other hard-to-heal wounds such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate CureXcell is an advanced wound care (AWC) therapy to treat such wounds by injecting living human white blood cells that have been activated to facilitate the healing process. CureXcell is in two pivotal Phase 3 double-blind clinical trials targeting an indication for the treatment of DFUs and VLUs. The Company holds product approval for CureXcell as a medical device in Israel for the treatment of chronic and other hard-to-heal wounds.

Macrocure Ltd

Leave a Reply

Macrocure Ltd - Is it time to Sell?

Top Brokerage Firms are advising their investors on Macrocure Ltd. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.